Jefferies initiated coverage of Tempus AI (TEM) with an Underperform rating and $35 price target The firm sees “secular tailwinds” in the oncology diagnostics space from improving therapies and declining sequencing costs, but also “ongoing polarization between the leaders and laggards.” Jefferies is cautious on Tempus due to concerns on its data business and reimbursement. The company has an “unclear catalyst path” in diagnostics, as it lacks a “true step-function catalyst similar to peers,” contends Jefferies.
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- William Blair health diagnostics analyst holds analyst/industry conference call
- Tempus AI announce strategic collaboration with Gilead
- Largest borrow rate increases among liquid names
- Tempus AI announces results from ALERT trial, study met primary endpoint
- Tempus AI price target lowered to $60 from $95 at Guggenheim